Brief: Knight Therapeutics And Sumitomo Pharma Enter Into Exclusive Licensing Agreements To Commercialize Sumitomo’S Canadian Portfolio
05/06/2025 12:16
Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS AND SUMITOMO PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENTS TO COMMERCIALIZE SUMITOMO’S CANADIAN PORTFOLIO KNIGHT THERAPEUTICS INC - DEAL INCLUDES UPFRONT AMOUNT OF C$25.4 MILLION KNIGHT THERAPEUTICS: MAY PAY FUTURE CONTINGENT PAYMENTS OF UP TO C$15.75 MILLION KNIGHT THERAPEUTICS INC - EXPECTED TO PAY C$7 MILLION FOR INVENTORY Source text: ID:nGNXbyJZJq Further company coverage: GUD.TO
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)